More than 800 community members recently turned out for the inaugural Arrest and Extinguish ALS event in Lenox, Massachusetts, raising $50,000 for amyotrophic lateral sclerosis (ALS) research. Twenty-two first-responder teams from the state’s Berkshires region gathered at the music venue Tanglewood to participate in a fun tug-of-war event…
News
RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
Injection of human neural stem cells into the spinal cord of people with amyotrophic lateral sclerosis (ALS) was found safe and did not cause adverse effects even two years after the transplant, results from a Phase 1 clinical trial show. Trial findings were published in the study, “Results…
Although people who develop amyotrophic lateral sclerosis (ALS) have altered levels of several blood metabolites — products of our cells’ metabolism — before disease onset, these changes do not enable reliable identification of who is at risk of having ALS, according to a large study. The research, “…
People with familial amyotrophic lateral sclerosis (ALS) related to the gene VAPB — known as ALS type 8 — can show subtle cognitive deficits and obvious behavioral changes, which may lead to clinically significant depression and anxiety, a Brazilian study shows. This data supports prior studies…
Using antibiotics may increase the risk of developing amyotrophic lateral sclerosis (ALS), with a higher number of prescriptions linked to greater risk, a nationwide study in Sweden suggests. However, the researchers caution that more studies are needed to prove a direct,…
News
Phase 3 Trial Results of Tirasemtiv Show Potential of Similar Therapies for ALS, Researchers Say
People with amyotrophic lateral sclerosis (ALS) who tolerated higher doses of tirasemtiv showed a trend toward slower decline in breathing muscle activity, although the difference was not statistically significant between those treated with the investigational therapy and those on a placebo, a Phase 3 clinical trial shows. These results may have…
Oxford BioDynamics has joined the REFINE-ALS study, a project designed to detect and measure the levels of specific biomarkers among people with amyotrophic lateral sclerosis (ALS), Mitsubishi Tanabe Pharma America (MTPA) announced. REFINE-ALS is sponsored by the MTPA and led by the Massachusetts General Hospital (MGH)…
With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies (NCATS) at…
Mitsubishi Tanabe Pharma America (MTPA) has launched a new database that locates healthcare providers, area infusion treatment centers, and in-home infusion services, with the goal of providing a one-stop convenient resource for amyotrophic lateral sclerosis (ALS) patients and caregivers. The nationwide directory is available within the ALS…
Recent Posts
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’